Witryna24 mar 2024 · SEATTLE, March 24, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and … Witryna12 kwi 2024 · SEATTLE, April 12, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of …
Investor Relations Impel Pharmaceuticals Inc.
Witryna12 kwi 2024 · SEATTLE, April 12, 2024 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of … WitrynaImpel Pharmaceuticals. 2024. 7. Smith TR, Winner P, Aurora SK, Jeleva M, Hocevar-Trnka J, Shrewsbury SB. STOP 301: a phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks … cryptography security+
Impel Pharmaceuticals Announces Strategic Reprioritization, …
WitrynaImpel Pharmaceuticals. 201 Elliott Avenue West, Suite 260 Seattle, WA 98119. Phone: 206.568.1466 WitrynaImpel Pharmaceuticals Inc. is a Seattle-based, commercial-stage pharmaceutical company developing first-in-class intranasal drug treatments for disorders with high … Impel Pharmaceuticals’ mission is to create and provide transformative therapies for … Impel Pharmaceuticals has developed a proprietary drug delivery technology … The efficacy of currently approved DHE-based medications is well-established … Impel Pharmaceuticals is currently developing INP105 with the goal to be a … Impel Pharmaceuticals is currently developing INP107, a non-invasive, self- … impel pharmaceuticals has developed its proprietary Precision Olfactory Delivery … Archive of posts categorized by Publications in Impel Pharmaceuticals. Impel … Impel attended the 2024 Headache Cooperative of the Pacific’s 14th Annual … WitrynaImpel Pharmaceuticals. 201 Elliott Avenue West, Suite 260 Seattle, WA 98119. Phone: 206.568.1466 crypto gold central